SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Maintain Significant 10.1% Stake in Immunovant Inc.
Beneficial Ownership Disclosure
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a continued beneficial ownership of 10.1% of Immunovant Inc.'s common stock as of February 28, 2025.
Summary
- FMR LLC and Abigail P. Johnson jointly filed an Amendment No. 2 to Schedule 13G, reporting their beneficial ownership in IMMUNOVANT INC.
- As of February 28, 2025, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 17,078,093.17 shares of IMMUNOVANT INC's Common Stock.
- This ownership represents 10.1% of the total outstanding class of IMMUNOVANT INC's common stock.
- FMR LLC holds sole voting power over 17,075,502.00 shares and sole dispositive power over 17,078,093.17 shares.
- Abigail P. Johnson holds sole dispositive power over 17,078,093.17 shares.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- FMR LLC is classified as a parent holding company or control person, with Abigail P. Johnson identified as a Director, Chairman, and Chief Executive Officer of FMR LLC, and a predominant owner of its voting shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G Amendment) disclosing passive beneficial ownership. It provides factual information about a significant stake held by FMR LLC and Abigail P. Johnson in Immunovant Inc. and does not contain positive or negative news about the issuer's operations or financial performance, thus maintaining a neutral sentiment.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates continued significant institutional investment in Immunovant Inc., a biotechnology company. Such filings are common for large asset managers like FMR LLC, reflecting their portfolio allocation decisions within the healthcare and biotech sectors. The passive nature of the investment suggests a long-term holding strategy rather than an activist stance.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, confirming continued passive ownership by FMR LLC and Abigail P. Johnson.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/26/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 02/28/2025 | Date of event which requires filing of this statement (measurement date for ownership). |
| 03/06/2025 | Date of signing and filing of the Schedule 13G Amendment No. 2. |
Keywords
Immunovant Inc, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.